Achmea Investment Management B.V. Invests $8.21 Million in Quest Diagnostics Incorporated (NYSE:DGX)

Achmea Investment Management B.V. purchased a new position in Quest Diagnostics Incorporated (NYSE:DGXGet Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 59,950 shares of the medical research company’s stock, valued at approximately $8,205,000. Achmea Investment Management B.V. owned 0.05% of Quest Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in DGX. Mystic Asset Management Inc. bought a new position in shares of Quest Diagnostics in the fourth quarter worth $25,000. Sandy Cove Advisors LLC bought a new stake in Quest Diagnostics during the first quarter worth about $28,000. Wagner Wealth Management LLC purchased a new position in shares of Quest Diagnostics in the 4th quarter worth about $35,000. Comprehensive Financial Consultants Institutional Inc. bought a new position in shares of Quest Diagnostics during the 4th quarter valued at about $38,000. Finally, NuWave Investment Management LLC bought a new stake in Quest Diagnostics in the 1st quarter worth approximately $40,000. Institutional investors own 88.87% of the company’s stock.

Analyst Upgrades and Downgrades

DGX has been the subject of a number of recent research reports. upgraded Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, July 7th. Morgan Stanley restated an “equal weight” rating and issued a $142.00 target price on shares of Quest Diagnostics in a research report on Monday, August 22nd. Six equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to, Quest Diagnostics presently has a consensus rating of “Hold” and an average target price of $148.50.

Insider Activity at Quest Diagnostics

In related news, Director Timothy M. Ring sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $133.47, for a total transaction of $266,940.00. Following the completion of the transaction, the director now owns 23,933 shares in the company, valued at $3,194,337.51. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.70% of the stock is owned by corporate insiders.

Quest Diagnostics Stock Performance

Shares of DGX stock opened at $130.00 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.42 and a current ratio of 1.54. Quest Diagnostics Incorporated has a fifty-two week low of $124.28 and a fifty-two week high of $174.16. The stock has a 50 day moving average price of $133.76 and a two-hundred day moving average price of $135.89. The company has a market capitalization of $15.16 billion, a P/E ratio of 10.82 and a beta of 1.01.

Quest Diagnostics (NYSE:DGXGet Rating) last announced its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.36 earnings per share for the quarter, beating the consensus estimate of $2.26 by $0.10. The firm had revenue of $2.45 billion during the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a return on equity of 24.62% and a net margin of 14.02%. The business’s revenue was down 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.18 earnings per share. Analysts expect that Quest Diagnostics Incorporated will post 9.69 earnings per share for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 19th. Investors of record on Tuesday, October 4th will be issued a dividend of $0.66 per share. The ex-dividend date is Monday, October 3rd. This represents a $2.64 dividend on an annualized basis and a dividend yield of 2.03%. Quest Diagnostics’s dividend payout ratio is presently 21.96%.

Quest Diagnostics Profile

(Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Further Reading

Want to see what other hedge funds are holding DGX? Visit to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with's FREE daily email newsletter.